Your browser doesn't support javascript.
loading
Balloon cells promote immune system activation in focal cortical dysplasia type 2b.
Zimmer, Till S; Broekaart, Diede W M; Luinenburg, Mark; Mijnsbergen, Caroline; Anink, Jasper J; Sim, Nam Suk; Michailidou, Iliana; Jansen, Floor E; van Rijen, Peter C; Lee, Jeong Ho; François, Liesbeth; van Eyll, Jonathan; Dedeurwaerdere, Stefanie; van Vliet, Erwin A; Mühlebner, Angelika; Mills, James D; Aronica, Eleonora.
Afiliação
  • Zimmer TS; Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Broekaart DWM; Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Luinenburg M; Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Mijnsbergen C; Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Anink JJ; Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Sim NS; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
  • Michailidou I; Department of Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands.
  • Jansen FE; Department of Paediatric Neurology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • van Rijen PC; Department of Neurosurgery, Brain Center, Rudolf Magnus Institute for Neuroscience, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Lee JH; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea.
  • François L; SoVarGen, Inc, Daejeon, Republic of Korea.
  • van Eyll J; Neurosciences Therapeutic Area, UCB Pharma, Braine-l'Alleud, Belgium.
  • Dedeurwaerdere S; Neurosciences Therapeutic Area, UCB Pharma, Braine-l'Alleud, Belgium.
  • van Vliet EA; Neurosciences Therapeutic Area, UCB Pharma, Braine-l'Alleud, Belgium.
  • Mühlebner A; Department of Translational Neuroscience, University of Antwerp, Wilrijk, Belgium.
  • Mills JD; Department of (Neuro)Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, The Netherlands.
  • Aronica E; Swammerdam Institute for Life Sciences, Center for Neuroscience, University of Amsterdam, Amsterdam, The Netherlands.
Neuropathol Appl Neurobiol ; 47(6): 826-839, 2021 10.
Article em En | MEDLINE | ID: mdl-34003514
AIMS: Focal cortical dysplasia (FCD) type 2 is an epileptogenic malformation of the neocortex associated with somatic mutations in the mammalian target of rapamycin (mTOR) pathway. Histopathologically, FCD 2 is subdivided into FCD 2a and FCD 2b, the only discriminator being the presence of balloon cells (BCs) in FCD 2b. While pro-epileptogenic immune system activation and inflammatory responses are commonly detected in both subtypes, it is unknown what contextual role BCs play. METHODS: The present study employed RNA sequencing of surgically resected brain tissue from FCD 2a (n = 11) and FCD 2b (n = 20) patients compared to autopsy control (n = 9) focusing on three immune system processes: adaptive immunity, innate immunity and cytokine production. This analysis was followed by immunohistochemistry on a clinically well-characterised FCD 2 cohort. RESULTS: Differential expression analysis revealed stronger expression of components of innate immunity, adaptive immunity and cytokine production in FCD 2b than in FCD 2a, particularly complement activation and antigen presentation. Immunohistochemical analysis confirmed these findings, with strong expression of leukocyte antigen I and II in FCD 2b as compared to FCD 2a. Moreover, T-lymphocyte tissue infiltration was elevated in FCD 2b. Expression of markers of immune system activation in FCD 2b was concentrated in subcortical white matter. Lastly, antigen presentation was strongly correlated with BC load in FCD 2b lesions. CONCLUSION: We conclude that, next to mutation-driven mTOR activation and seizure activity, BCs are crucial drivers of inflammation in FCD 2b. Our findings indicate that therapies targeting inflammation may be beneficial in FCD 2b.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epilepsia / Malformações do Desenvolvimento Cortical / Serina-Treonina Quinases TOR / Malformações do Desenvolvimento Cortical do Grupo I / Sistema Imunitário Limite: Adolescent / Child / Humans / Male / Middle aged Idioma: En Revista: Neuropathol Appl Neurobiol Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epilepsia / Malformações do Desenvolvimento Cortical / Serina-Treonina Quinases TOR / Malformações do Desenvolvimento Cortical do Grupo I / Sistema Imunitário Limite: Adolescent / Child / Humans / Male / Middle aged Idioma: En Revista: Neuropathol Appl Neurobiol Ano de publicação: 2021 Tipo de documento: Article